COVID-19 Therapeutics: Resources for Health Care Professionals and Public Health Officials
COVID-19 therapeutics can be used to prevent or treat eligible non-hospitalized patients who have mild to moderate COVID-19 symptoms. Prevention and early treatment for eligible patients can help improve patient outcomes, reduce stress on healthcare facilities, and even save lives.
At this time, Veklury (remdesivir) and Paxlovid (nirmatrelvir co-packaged with ritonavir) for adults (ages 18 and older) are approved therapeutics. Paxlovid for pediatric patients (ages 12-17) and Lagevrio are available under an FDA’s Emergency Use Authorization (EUA).
HHS/ASPR purchased supplies of COVID-19 therapeutic products for outpatient use, and is working with state and territorial health departments as well as national healthcare and medical organizations and associations to make these treatments widely accessible across the country.
Outpatient COVID-19 Therapeutics
Previously Available COVID-19 Therapeutic Products
The products listed below are not currently authorized in the U.S because they are not expected to be effective against the currently circulating SARS-CoV-2 variants. Providers with non-expired inventory of these products are encouraged to retain them, as they have the potential to treat future variants more effectively.
Increasing Access to COVID-19 Therapeutics